ImmunityBio, Inc.
IBRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001326110
In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in ImmunityBio, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 386
- +113 vs. Q4 2025
- Shares held
- 178.6M
- +42.4M (+31.1%) vs. Q4 2025
- Total value
- $1.36B
- +$1.09B (+399.1%) vs. Q4 2025
- New holders
- 145
- 138 more added
- Sold out
- 32
- 59 more reduced
5 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IBRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 405 | $1.76B |
| Q1 2026 | 386 | $1.36B |
| Q4 2025 | 278 | $338.3M |
| Q3 2025 | 264 | $352.1M |
| Q2 2025 | 242 | $327.9M |
| Q1 2025 | 211 | $239.4M |
| Q4 2024 | 202 | $211.8M |
| Q3 2024 | 182 | $255.6M |
| Q2 2024 | 194 | $391.1M |
| Q1 2024 | 166 | $356.9M |
| Q4 2023 | 148 | $288.9M |
| Q3 2023 | 132 | $84.1M |
| Q2 2023 | 118 | $108.7M |
| Q1 2023 | 147 | $84.1M |
| Q4 2022 | 140 | $256.0M |
| Q3 2022 | 126 | $196.3M |
| Q2 2022 | 132 | $123.1M |
| Q1 2022 | 149 | $199.8M |
| Q4 2021 | 141 | $209.7M |
| Q3 2021 | 121 | $310.9M |
| Q2 2021 | 118 | $390.1M |
| Q1 2021 | 116 | $378.9M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding ImmunityBio, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Godsey & Gibb Associates | 0 | $0 | 0.00% | −46,100−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −44,780−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −42,133−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −36,207−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −35,180−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −35,125−100.0% | Sold out |
| Diversify Advisory Services, LLC | 0 | $0 | 0.00% | −10,896−100.0% | Sold out |
| Mackenzie Financial Corp | 0 | $0 | 0.00% | −14,416−100.0% | Sold out |
| Farringdon Capital, Ltd. | 0 | $0 | 0.00% | −14,316−100.0% | Sold out |
| AlphaGrep UK Ltd | 0 | $0 | 0.00% | −11,539−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −9,272−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| JFS Wealth Advisors, LLC | 0 | $0 | 0.00% | −213−100.0% | Sold out |
| Adirondack Trust Co | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| HighMark Wealth Management LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Pension & Wealth Management Advisors, Inc. | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| DiNuzzo Private Wealth, Inc. | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |
| ORG Partners LLC | – | – | – | – | Not filed |